TAK logo

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)

$21.59

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TAK

Market cap

$68.22B

EPS

0.21

P/E ratio

84.1

Price to sales

2.02

Dividend yield

2.856%

Beta

-0.031153

Price on TAK

Previous close

$21.43

Today's open

$21.73

Day's range

$21.56 - $21.86

52 week range

$13.91 - $21.86

Profile about TAK

CEO

Julie Kim

Employees

47029

Headquarters

Tokyo,

Exchange

New York Stock Exchange

Shares outstanding

3.16B

Issue type

American Depository Receipt

TAK industries and sectors

Healthcare

Pharmaceuticals

News on TAK

Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle

Takeda said on Thursday its narcolepsy pill, the first treatment to target the underlying cause ​of the rare sleep disorder, is now available in the US after ‌a Drug Enforcement Administration decision removed the final regulatory hurdle for its rollout.

news source

Reuters • Nov 12, 2026

news preview

Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States.

news source

Business Wire • Nov 12, 2026

news preview

What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call

Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to support profitability.

news source

MarketBeat • Oct 30, 2026

news preview

Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow

Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but operating cash flow declined to $2.74B, highlighting weak underlying cash generation. New products like Mimrylo and Orzeyful are slow to ramp and currently contribute minimally, while Entyvio remains the key revenue driver.

news source

Seeking Alpha • Oct 30, 2026

news preview

Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang

Takeda Pharmaceutical Co Ltd (NYSE:TAK) on Thursday reported second-quarter adjusted earnings of 48 cents per share, beating the consensus of 31 cents.

news source

Benzinga • Oct 29, 2026

news preview

Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 29, 2026

news preview

Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of zasocitinib, and additional clinical evidence across the late-stage pipeline. Takeda's focus remains on execution against the first horizon of its growth strategy: succe.

news source

Business Wire • Oct 29, 2026

news preview

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical On.

news source

Business Wire • Oct 23, 2026

news preview

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent.

news source

Business Wire • Oct 19, 2026

news preview

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.

news source

Business Wire • Oct 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)

Open an M1 investment account to buy and sell Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TAK on M1